Buffett Cancer Center Offers New Pancreatic Cancer Therapy Daraxonrasib
Patients at the Fred & Pamela Buffett Cancer Center now have access to a promising new therapy that has generated national attention for its potential to improve outcomes for people with advanced pancreatic cancer. Patients with previously treated metastatic pancreatic cancer can receive daraxonrasib through an Expanded Access Program (EAP), providing an opportunity to receive the investigational therapy while it awaits review by the U.S. Food and Drug Administration.
Nebraska Cancer Specialists First in Region to Offer New Pancreatic Cancer Therapy
Nebraska Cancer Specialists (NCS) is now offering eligible patients access to a promising investigational treatment for metastatic pancreatic cancer through a U.S. Food and Drug Administration (FDA) Expanded Access Program (EAP). NCS is currently the only practice in the region providing access to this treatment through its nationally recognized clinical research program.
State To Match $15 Million In Funding For Fight Against Pancreatic Cancer
The University of Nebraska Medical Center, Nebraska Medicine and the University of Nebraska Foundation have successfully secured the funds necessary to qualify for the state match funding of $15 million for the Pancreatic Cancer Center of Excellence, university officials announced this week.